Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation

被引：0
|
作者：
Kim, J. H. [1 ]
Kim, J. E. [1 ]
Kim, S. Y. [1 ]
Kim, K-P. [1 ]
Hong, Y. S. [1 ]
Kim, T. W. [1 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study
    Jwa Hoon Kim
    Sun Young Kim
    Kyu-pyo Kim
    Tae Won Kim
    Sun Young Chae
    Hwa Jung Kim
    Jae Seung Kim
    Jin-Sook Ryu
    Dae Hyuk Moon
    Jeong Eun Kim
    Yong Sang Hong
    Targeted Oncology, 2019, 14 : 689 - 697
  • [2] Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study
    Kim, Jwa Hoon
    Kim, Sun Young
    Kim, Kyu-pyo
    Kim, Tae Won
    Chae, Sun Young
    Kim, Hwa Jung
    Kim, Jae Seung
    Ryu, Jin-Sook
    Moon, Dae Hyuk
    Kim, Jeong Eun
    Hong, Yong Sang
    TARGETED ONCOLOGY, 2019, 14 (06) : 689 - 697
  • [3] Comment on: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”
    Yusuf Ziya Şener
    Targeted Oncology, 2020, 15 : 411 - 411
  • [4] Comment on: "Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study"
    Sener, Yusuf Ziya
    TARGETED ONCOLOGY, 2020, 15 (03) : 411 - 411
  • [5] Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer
    Sugita, Kazuo
    Kawakami, Kazuyoshi
    Yokokawa, Takashi
    Mae, Yutaro
    Toya, Wataru
    Hagino, Akane
    Suzuki, Kenichi
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hama, Toshihiro
    ANTICANCER RESEARCH, 2015, 35 (07) : 4059 - 4062
  • [6] Authors' Reply to Yusuf Ziya Sener: "Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study"
    Kim, Jwa Hoon
    Kim, Jeong Eun
    Hong, Yong Sang
    TARGETED ONCOLOGY, 2020, 15 (03) : 413 - 414
  • [7] Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”
    Jwa Hoon Kim
    Jeong Eun Kim
    Yong Sang Hong
    Targeted Oncology, 2020, 15 : 413 - 414
  • [8] TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib
    Kito, Yosuke
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Komori, Azusa
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Mori, Keita
    Muro, Kei
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [10] Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment
    Saito, Yoshitaka
    Takekuma, Yoh
    Komatsu, Yoshito
    Sugawara, Mitsuru
    SUPPORTIVE CARE IN CANCER, 2022, 30 (12) : 10203 - 10211
12345